Climb Bio, Inc. CLYM
Climb Bio, Inc. (Nasdaq: CLYM) is a cardio-renal-metabolic drug developer. Its lead program, budoprutug (IV), is in Phase 2 for primary membranous nephropathy (pMN). Its next catalyst on record is budoprutug IV: Additional ITP data from 500 mg and 1000 mg cohorts (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: budoprutug IV — Additional ITP data from 500 mg and 1000 mg cohorts (Q4 2026). 6 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| budoprutug IV (PrisMN) | primary membranous nephropathy | antibody | Phase 2 |
| budoprutug IV | immune thrombocytopenia (ITP), Phase 1b/2a | antibody | Phase 1 |
| budoprutug IV | systemic lupus erythematosus, global Phase 1b and China Phase 1b/2a | antibody | Phase 1 |
| budoprutug SC | autoimmune disease (SC formulation) | antibody | Phase 1 |
| CLYM116 | IgA nephropathy and other B-cell mediated diseases | antibody | Phase 1 |
Recent results and decisions
- Oct 23, 2026positive Phase 1 data for CLYM116/MIL116 showed >90% free APRIL suppression through 12 weeks and ~70% Gd-IgA1 reduction following a single dose, supporting Q12W dosing.
Following a single 800 mg dose, ~70% reduction in Gd-IgA1 and ~60% reduction in IgA were observed at 12 weeks.
Filing - Sep 3, 2026positive CLYM116 Phase 1 showed ~29-day half-life, >90% free APRIL suppression and ~60-75% IgA/Gd-IgA1/IgM suppression through 12 weeks after a single 320 mg SC dose; no SAEs, DLTs or hypogammaglobulinemia.
>90% free APRIL suppression following a single, SC injection of 320 mg, with potential for sustained APRIL suppression with a Q12W dosing regimen
Filing - Aug 6, 2026positive Initial Phase 1b ITP data (EHA, June 2026): favorable safety at 250 and 500 mg, robust B-cell depletion and encouraging platelet responses in the 250 mg cohort; no numbers given.
Initial safety data from the 250 mg and 500 mg cohorts demonstrated favorable safety and tolerability, and initial efficacy data from the 250 mg cohort demonstrated robust B-cell depletion, and encouraging platelet responses.
Filing
4 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.